Neuren Pharmaceuticals Ltd NEU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 126.77M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 110.76
- Price/Sales
- 38.27
- Dividend Yield (Trailing)
- 0.74%
- Dividend Yield (Forward)
- 1.48%
- Dividend Payment Schedule
- —
- Total Yield
- 0.74%
Company Profile
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.neurenpharma.com
Valuation
|
Metric
|
NEU
|
|---|---|
Price/Earnings (Normalized) | 110.76 |
Price/Book Value | 7.71 |
Price/Sales | 38.27 |
Price/Cash Flow | 519.93 |
Price/Earnings
NEU
Financial Strength
|
Metric
|
NEU
|
|---|---|
Quick Ratio | 40.09 |
Current Ratio | 46.45 |
Interest Coverage | — |
Quick Ratio
NEU
Profitability
|
Metric
|
NEU
|
|---|---|
Return on Assets (Normalized) | 6.63% |
Return on Equity (Normalized) | 6.76% |
Return on Invested Capital (Normalized) | 4.16% |
Return on Assets
NEU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|P$<VmpF | LOCK|ZSs@ | $128B | |||
| Moderna Inc
MRNA
| LOCK|&@?Tcn | LOCK|N? | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|v^@mW> | LOCK|!%h? | $76B | |||
| argenx SE ADR
ARGX
| LOCK|FxQZX&% | LOCK|r$y | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&@jb<th | LOCK|cTT | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<qc^F# | LOCK|P%D&! | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?h!t>v^ | LOCK|%Y?H< | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|$>vsCM> | LOCK|f^N | $24B | |||
| Incyte Corp
INCY
| LOCK|D!#H%t | LOCK|$<% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|k!?$@N | LOCK|^$B | $15B |
United States